Navigation Links
Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors
Date:10/1/2008


Former FDA Deputy Director and Talecris executive adds extensive

clinical, regulatory and manufacturing experience to Company's Board

TSX: HAE

MONTREAL, Oct. 1 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX: HAE) announced today the appointment of Thomas J. Lynch, J.D., Ph.D. to the Company's Board of Directors. Dr. Lynch, former Deputy Director, Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), currently serves as Senior Vice President Compliance, Regulatory Affairs and Public Policy for Talecris Biotherapeutics.

"Dr. Lynch brings extensive clinical, regulatory and manufacturing experience in the area of blood products and a broad strategic perspective to our Board of Directors. We are pleased to welcome him as an independent director," said Joseph Galli, Haemacure's Chairman and Chief Executive Officer. "Thomas' distinguished background and relevant expertise will be a valuable addition to our Board as we continue to make progress toward initiating a pivotal Phase II/III clinical trial for our lead product candidate, Hemaseel(R)HMN (fibrin sealant), for biosurgical hemostasis" concluded Mr. Galli.

From 2003-2005, Dr. Lynch served as Vice President, Regulatory Affairs and Quality Assurance at CryoLife, Inc., a manufacturer of medical tissues, heart valves and oncology drugs, where he was responsible for, among other things, ensuring compliance with domestic and international laws, regulations, governing the design, manufacture, and distribution of medical devices, biological products and human tissues. Prior to joining CryoLife, Dr. Lynch served as Senior Vice President, Regulatory Affairs and Quality Assurance at Clearant Inc., a biotechnology company developing pathogen inactivation technology for the biological products market. Dr. Lynch also served as Deputy Director, Division of Hematology, Office of
'/>"/>

SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
2. Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
3. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
4. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
5. Haemacure Reports on Financing Progress and Second Quarter Results
6. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
7. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Haemacure financing receives shareholder consent - Series B Warrants are amended
9. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
10. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
11. Haemacure Reports on its annual general and special meeting of shareholders

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...Newswire-USNewswire/ -- The following was released...e Insurrecta Nex. ,, Mr. Terry and his associa...keep child-killing by abortion out of any health c... is a great first step to victory -- a touchdown i...ng ahead of us. Our rejoicing must be tempered by ...
(Date:11/8/2009)...s Who Sides With Working Families vs. Insurance Co...-USNewswire/ -- On the heels of an historic late n...od, balanced health care reform bill, the Pennsylv...,s U.S. representatives voted on HR 3962, the Affo...islation, which passed Saturday evening by a vote ...
(Date:11/8/2009).... 8 March of Dimes host...n to recognize prominent individuals who are celeb...e models for March of Dimes commitment to improve ...es November Prematurity Awareness Month campaign, ...the fight for preemies! ,, (Photo: http://www...
(Date:11/7/2009)... Speaker Nancy Pelosi s...962, the Affordable Health Care for America Act. ...ht. Below are the Speaker,s remarks. ,, "Mada...oment for our nation and for American families. F...litical philosophy -- as far back as Teddy Rooseve...
(Date:11/7/2009)...swire-USNewswire/ -- The American Medical Associat...f Health at the Family Violence Prevention Fund, w...t its semi-annual policy-making meeting. The Cita...r the AMA House of Delegates bestows on a non-phys...i-bin/prnh/20081209/AMALOGO ) ,, "Ms. James h...
Breaking Medicine News(10 mins):Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA Honors Family Violence Prevention Expert 2
...Minn., March 26 Pharmacy benefit manager Prime Th...nical pharmacists, Patrick Gleason, PharmD, FCCP, ...armD were awarded the Journal of Managed Care Phar...laims data indicating risk for an adverse cardiova...
... Provide Strategic Direction and Execute Creative ...ermanente has chosen Digitas, Advertising Age,s ...toB Magazine,s 2008 Top Agency, as its online cre...cessful "Thrive" advertising campaign that the hea...
...Inspired Features and a Redesigned Interface, Onco... March 26 Compendia Bioscience announces the rele...latest incarnation of the company,s flagship produ...improve results of cancer drug development efforts...
...THICUM, Md., March 26 The statement below is att...ican Urological Association. This statement is bei...ished in the New England Journal of Medicine a...studies about prostate-specific antigen (PSA) test...
...cent of Surveyed MCO Pharmacy Directors Say They W...r Juvenile Idiopathic Arthritis and Pediatric Croh...on Resources , , WALTHAM, Mass., March 26 Decisi...atologists have altered their prescription pattern...
...ants weaken lungs, defenses against free radicals,...ealthDay News) -- Variations in several genes can ...well as how vulnerable they are to secondhand smok...al exposures such as tobacco smoke and air polluta...
Other Medicine News:Health News:Prime Pharmacists Recognized by the Journal of Managed Care Pharmacy 2Health News:Kaiser Permanente Names Digitas Agency of Record for Direct Marketing 2Health News:Kaiser Permanente Names Digitas Agency of Record for Direct Marketing 3Health News:Compendia Bioscience Releases Oncomine Concepts Edition 4.0 2Health News:Compendia Bioscience Releases Oncomine Concepts Edition 4.0 3Health News:American Urological Association Statement in Support of Prostate-Specific Antigen Testing 2Health News:American Urological Association Statement in Support of Prostate-Specific Antigen Testing 3Health News:As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis 2Health News:As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis 3Health News:Genes May Boost Harm to Kids From Secondhand Smoke 2
(Date:11/6/2009)... DETROIT, Nov. 6 Caraco ... ) has launched ketorolac tromethamine ophthalmic ... US Food and Drug Administration (FDA) for Sun Pha...generic Acular® ophthalmic solution on the fi... of ketorolac is therapeutically equivalent to Acu...
(Date:11/6/2009)... SAN DIEGO, Nov. 6 NuVas...ny focused on developing products for minimally di...ced today the appointment of Michael J. Lambert as...cer, effective November 9, 2009. The Company also... updates. ,, "Michael will be an excellent comp...
(Date:11/6/2009)... SAN DIEGO, Nov. 6 Ardea...gy company focused on the development of small-mol...er and human immunodeficiency virus (HIV), today r...ts for the third quarter and nine months ended Sep...m.com/cgi-bin/prnh/20091104/ARDEALOGO ) ,, "Sin...
Breaking Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back 14204 1Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back 14204 2Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back 14204 3Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back 14204 4Rural roads dangerous for young drivers 57955 1Rural roads dangerous for young drivers 57955 2NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 1NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 2NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 3NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 4NKTR 102 Shows Encouraging Anti Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplin 5029 5
...f 2008 --,-- Presentation at the Seventh Annual JM...celed; webcast of corporate update scheduled durin...22nd at 9:30 a.m. PT --, SAN DIEGO, May 20 Ardea...d that data was presented on the Company,s,lead mi...9, demonstrating,potent activity in mouse models o...
... presented today at the 39th Annual Digestive Dise...ts at increased risk for colorectal,cancer who com...detection,of cancerous lesions occurred an average...uring the three- or five-year study-required colon...group occurred 18.4 months,earlier., Data present...
Other Medicine Technology:Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 2Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 3Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 4Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds 2Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds 3Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds 4Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds 5
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products: